November 23, 2015

Greenstone received final approval from the Food and Drug Administration for its generic Zyvox. 

November 23, 2015

Perrigo is buying a Crohn’s disease treatment from AstraZeneca. 

November 20, 2015

Alchemia’s shareholders approved the sale of Fondaparinux at the company’s annual general meeting held on Nov. 10.

November 20, 2015

Specialty medications represent only 1% of all prescriptions but, in 2014, these medications resulted in over 31% of all drug spending.

November 20, 2015

With the U.S. Treasury announcing plans to crack down on tax-inversion deals on Thursday, pharmaceutical giants Pfizer and Allergen have accelerated their merger talks, according to reports. The potential $150 billion deal could see Pfizer redomicile in Ireland. (Reuters)

November 19, 2015

The drug will be available in 5-, 7.5-, 10-, 12.5, 15-, 20- and 30-mg tablets.

November 19, 2015

The healthcare logistics industry has seen significant improvements in product security and regulatory compliance across the supply chain. 

November 18, 2015

Steven Collis has served as president and CEO of AmerisourceBergen since July 2011 and a director since May 2011.

November 18, 2015
The dispensing rate of generic medicines will increase from 88% to as high as 92% by 2020, the IMS Institute for Healthcare Informatics reported
 
November 17, 2015

Ajanta is launching its fifth generic product in the U.S. that has received Food and Drug administration approval. 

November 17, 2015

Mylan has launched its generic of Axert, a treatment for migraines. 

November 16, 2015

Mylan has launched two generics — one for diabetes and another for HIV — following final Food and Drug Administration approval. 

November 13, 2015

Perrigo’s shareholders did not tender a majority of the company’s shares to Mylan by 8 a.m. EST Friday, effectively ending Mylan’s acquisition attempt. 

November 11, 2015

A merger frenzy has hit the generics sector this year with a spate of acquisitions and hostile-takeover bids making headlines and reshaping the industry.

November 11, 2015

The drug is indicated to treat and prevent low levels of potassium (hypokalemia). 

November 11, 2015

Rapidly rising prices for many generics, regulations that could restrict patients’ access to these medications, a Food and Drug Administration backlog in getting new drugs approved and market consolidation that is reducing competition are all making some wonder how much longer generics will continue to be affordable.

November 11, 2015

As 2015 draws to a close, the year is on track to be one in which the value of the branded drugs losing their patent protection approaches an all-time high. The dozens of drugs that will have lost their patent protection this year are estimated to have global sales of $44 billion a year — the highest total since $53 billion worth of medications went off patent in 2012.

November 10, 2015

New Jersey Gov. Chris Christie this week signed legislation allowing pharmacists to subsistute FDA-approved biosimilar products for biologics, and Generic Pharmaceutical Association voiced its support for the move. 

November 10, 2015

Teva Canada was granted approval for its Avelox generic by Health Canada on Tuesday. 

November 9, 2015

Glenmark Pharmaceuticals has gained approval from the FDA for its generic Lotrisone. 

November 5, 2015

The new website is tailored to its user, with a product section that customizes results based on who is searching — patients, pharmacists or partners. 

November 3, 2015

With the completion of this step all Mylan needs is word from Perrigo’s shareholders on whether or not they will accept the company’s $27 billion acquisition offer, which was tendered on Sept. 14. 

November 3, 2015

A new study by IMS Health for the Generic Pharmaceutical Association is highlighting the savings that generic drugs bring to patients. 

November 3, 2015
The Regulartory Affairs Professionals Society is reporting that as part of the recently passed budget deal that the president signed Monday, generics companies whose prices rise beyond the Average Manufacturer Price that’s adjusted for inflation will have to pay higher rebates. “The amount of the rebate specified in this paragraph for a rebate period, with respect to each dosage form and strength of a covered outpatient drug other than a single source drug or an innovator multiple source drug of a manufacturer, shall be increased in the manner that the rebate for a dosage form and strength of a single source drug or an innovator multiple source drug is increased,” the act says. (RAPS)